{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:28:57Z","timestamp":1766428137667},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.lpm.2016.11.020","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T01:16:08Z","timestamp":1482455768000},"page":"337-341","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optic neuritis associated to treatment with infliximab"],"prefix":"10.1016","volume":"46","author":[{"given":"Anne","family":"Landais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosan","family":"Fanhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2016.11.020_bib0100","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.020_bib0105","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","article-title":"Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review","volume":"40","author":"Cruz Fern\u00e1ndez-Espartero","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.020_bib0110","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2008.11.002","article-title":"Inflammatory demyelinating events following treatment with anti-tumor necrosis factor","volume":"45","author":"Fromont","year":"2009","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.020_bib0115","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.lpm.2016.11.020_bib0120","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00415-010-5591-7","article-title":"Neurological adverse events associated with anti-tumor necrosis factor-alpha treatment","volume":"257","author":"Tristano","year":"2010","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.020_bib0125","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the university of British Columbia MS\/MRI Analysis Group","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.lpm.2016.11.020_bib0130","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.lpm.2016.11.020_bib0135","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"Van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2016.11.020_bib0140","first-page":"1027","article-title":"Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance","volume":"33","author":"Toussirot","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2016.11.020_bib0145","first-page":"240","article-title":"Reply to: \u201cAdalimumab-associated multiple sclerosis\u201d","volume":"34","author":"Toussirot","year":"2007","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.020_bib0150","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1212\/WNL.38.3.371","article-title":"Autoimmunity in multiple sclerosis","volume":"38","author":"De Keyser","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2016.11.020_bib0155","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/apt.12997","article-title":"Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients","volume":"41","author":"De Felice","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.020_bib0160","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.020_bib0165","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMoa011341","article-title":"A longitudinal study of abnormalities on MRI and disability from multiple sclerosis","volume":"346","author":"Brex","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.020_bib0170","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.020_bib0175","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"\u201cInternational consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)\u201d","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1016\/j.lpm.2016.11.020_bib0180","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1196\/annals.1361.100","article-title":"Autoimmunity and anti-TNF-alpha agents","volume":"1051","author":"Atzeni","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.lpm.2016.11.020_bib0185","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/ard.2003.018093","article-title":"Treatment with tumour necrosis factor \u03b1 antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies","volume":"63","author":"Jonsdottir","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.lpm.2016.11.020_bib0190","doi-asserted-by":"publisher","first-page":"R535","DOI":"10.1186\/ar1440","article-title":"Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study","volume":"6","author":"Ferraro-Peyret","year":"2004","journal-title":"Arthritis Res Ther"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216303943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216303943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T12:56:39Z","timestamp":1536152199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216303943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0755498216303943"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.11.020","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optic neuritis associated to treatment with infliximab","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}